Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Trial Of Iberdomide-Combinations In Patients With Positive Minimal Residual Disease (>10-5) After Autologous Hematopoietic Cell Transplantation In The Upfront Management Of Patients With Multiple Myeloma

NCT05434689 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT05434689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05434689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Trial Of Iberdomide-Combinations In Patients With Positive Minimal Residual Disease (>10-5) After Autologous Hematopoietic Cell Transplantation In The Upfront Management Of Patients With Multiple Myeloma
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 18, 2023
Completion date
August 31, 2028
Enrollment
80 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma